<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04557150</url>
  </required_header>
  <id_info>
    <org_study_id>BP42233</org_study_id>
    <secondary_id>2020-002012-46</secondary_id>
    <nct_id>NCT04557150</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of RO7425781 in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)</brief_title>
  <official_title>An Open-Label, Multicenter, Phase I Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of RO7425781 in Participants With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human, open-label, uncontrolled, multi-center, monotherapy,&#xD;
      dose-escalation and dose expansion study. RO7425781 will be administered to participants with&#xD;
      r/r MM for whom no standard-of-care treatment exists or who are intolerant to those&#xD;
      established therapies. The study consists of two parts: dose-escalation of RO7425781 (Part 1)&#xD;
      and a randomized dose expansion of RO7425781 (Part 2).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2020</start_date>
  <completion_date type="Anticipated">July 13, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 13, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to 69 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Up to 69 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 69 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 69 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Up to 69 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 69 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Anti-Drug Antibodies (ADAs) to RO7425781</measure>
    <time_frame>Up to 69 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) of RO7425781</measure>
    <time_frame>Up to 69 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum concentration (Tmax) of RO7425781</measure>
    <time_frame>Up to 69 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum concentration (Cmin) of RO7425781</measure>
    <time_frame>Up to 69 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SC Bioavailability (F) of RO7425781</measure>
    <time_frame>Up to 69 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F) of RO7425781</measure>
    <time_frame>Up to 69 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss) of RO7425781 (IV only)</measure>
    <time_frame>Up to 69 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) at various time intervals of RO7425781</measure>
    <time_frame>Up to 69 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Part I: Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RO7425781 as intravenous (IV) infusion and/or subcutaneous (SC) injection in a step-up dosing fashion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II: Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Expansion cohorts with IV and/or SC administration will be initiated at the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) determined from Part I: Dose Escalation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7425781</intervention_name>
    <description>RO7425781 will be administered via IV/SC administration. The MTD/RP2D determined during Part I: Dose Escalation will be administered during Part II: Dose Expansion. RO7425781 will be administered as per the dosing schedule defined in Part I.</description>
    <arm_group_label>Part I: Dose Escalation</arm_group_label>
    <arm_group_label>Part II: Dose Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previously diagnosed with Multiple Myeloma (MM) based on standard criteria.&#xD;
&#xD;
          -  Dose Escalation Phase: Participants with r/r MM who have previously received therapy&#xD;
             with an Immunomodulatory drug (IMiD) and Proteasome Inhibitor (PI) and are intolerant&#xD;
             to or have no other option for standard-of-care treatment according to the&#xD;
             Investigator.&#xD;
&#xD;
          -  Dose Expansion Phase: Participants with r/r MM who have received at least three prior&#xD;
             treatments and are refractory to an IMiD, a PI, and a CD38-targeted therapy.&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks.&#xD;
&#xD;
          -  Agreement to provide protocol-specific biopsy material.&#xD;
&#xD;
          -  AEs from prior anti-cancer therapy resolved to Grade =&lt;1.&#xD;
&#xD;
          -  Measurable disease.&#xD;
&#xD;
          -  For female participants of childbearing potential: agreement to remain abstinent&#xD;
             (refrain from heterosexual intercourse), use contraceptive measures and refrain from&#xD;
             donating eggs.&#xD;
&#xD;
          -  For male participants: agreement to remain abstinent (refrain from heterosexual&#xD;
             intercourse), use contraceptive measures and refrain from donating sperm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to comply with protocol-mandated hospitalization and activities&#xD;
             restrictions.&#xD;
&#xD;
          -  Pregnant or breastfeeding, or intending to become pregnant during the study or within&#xD;
             3 months after the last dose of study drug.&#xD;
&#xD;
          -  Prior use of any monoclonal antibody, radioimmunoconjugate, or antibody-drug conjugate&#xD;
             within 2 weeks before first RO7425781 administration.&#xD;
&#xD;
          -  Prior treatment with systemic immunotherapeutic agents within 2 weeks before first&#xD;
             RO7425781 administration.&#xD;
&#xD;
          -  Treatment-related, immune-mediated AEs associated with prior immunotherapeutic agents.&#xD;
&#xD;
          -  Treatment with radiotherapy, any chemotherapeutic agent, or treatment with any other&#xD;
             anti-cancer agent (investigational or otherwise) within 2 weeks except for alkylating&#xD;
             agents (e.g., melphalan) within 28 days, prior to first RO7425781 administration.&#xD;
             Limited field palliative radiotherapy for bone pain or for soft tissue lesions is&#xD;
             allowed.&#xD;
&#xD;
          -  Autologous or allogeneic stem cell transplantation (SCT) within 100 days prior to&#xD;
             first RO7425781 administration and/or signs of chronic graft versus host disease or&#xD;
             ongoing immunosuppressive medication.&#xD;
&#xD;
          -  Prior solid organ transplantation.&#xD;
&#xD;
          -  Any medical condition or abnormality in clinical laboratory tests that, in the&#xD;
             Investigator's or Medical Monitor's judgment, precludes the participant's safe&#xD;
             participation in and completion of the study, or which could affect compliance with&#xD;
             the protocol or interpretation of results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: BP42233 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Center</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet; Hæmatologisk Klinik</name>
      <address>
        <city>København Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU Lille - Hôpital Claude Huriez; Service des Maladies du Sang</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU NANTES - Hôtel Dieu; Service d'Hematologie Clinique</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital De Haut Leveque; Hematologie Clinique</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Nazionale dei Tumori di Napoli - Pascale Ematologia Oncologica</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fond. IRCCS Istituto Nazionale Tumori; S. C. Ematologia</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Clinico Humanitas; Med Onc &amp; Hemat</name>
      <address>
        <city>Rozzano</city>
        <state>Lombardia</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla; Servicio de Hematologia</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra; Servicio de Hematologia</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Salamanca;Servicio de Hematologia</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust; NIHR UCLH Clinical Research Facility</name>
      <address>
        <city>London</city>
        <zip>W1T 7HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 17, 2020</study_first_submitted>
  <study_first_submitted_qc>September 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2020</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

